Jodie Morrison

Chief Executive Officer, Q32 Bio Inc.

Search every verified Jodie Morrison interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Jodie Morrison, CEO of Q32 Bio, discussed her career and leadership approach in a September 2026 interview. She recounted initially declining the CEO role at Tokai Pharmaceuticals and accepting it only after securing a condition that her board chair meet with her weekly until she felt prepared. Morrison said she believes first-time CEOs often try to "fake it till you make it" and are unwilling to ask for help, and she described being open about her own uncertainty when starting the position. Morrison also discussed her efforts to build professional networks for executives, including founding a CEO forum that she said now has 300 members and participating in groups like the biotech sisterhood. She commented on progress for women in the industry, saying that while there has been "tremendous headway," political negativity around diversity, equity, and inclusion discussions may have contributed to a "stall point." Under her leadership, Q32 Bio reported positive Phase 2 data for bempikibart in severe alopecia areata in 2026 and completed a $200 million public offering, following a restructuring in 2025.